Liver fluke drug proves safe in largest study yet
NCT ID NCT04230148
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the safety and effectiveness of the drug EGATEN (triclabendazole) in 301 people aged 6 and older with fascioliasis, a parasitic liver infection. Participants received two doses of EGATEN 12 hours apart and were followed for 90 days. The goal was to see if the drug is safe and can cure the infection by clearing symptoms and lab abnormalities.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FASCIOLIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
Medellín, Antioquia, 050010, Colombia
-
Novartis Investigative Site
Alexandria, 21131, Egypt
-
Novartis Investigative Site
Cairo, 11617, Egypt
-
Novartis Investigative Site
San Martín de Porres, Lima region, 31, Peru
-
Novartis Investigative Site
Cusco, 84, Peru
-
Novartis Investigative Site
Istanbul, Fatih, 34093, Turkey (Türkiye)
-
Novartis Investigative Site
Gaziantep, Sehitkamil, 27310, Turkey (Türkiye)
-
Novartis Investigative Site
Sur, 21280, Turkey (Türkiye)
-
Novartis Investigative Site
Van, 65080, Turkey (Türkiye)
-
Novartis Investigative Site
Qui Nhon, Binh Dinh, 590000, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.